CC2021: Intra-articular Injections of Mesenchymal Stem Cells Without Adjuvant Therapies for Knee Osteoarthritis (September 2021)-CC2021: Intra-articular Injections of Mesenchymal Stem Cells Without Adjuvant Therapies for Knee Osteoarthritis (September 2021)

CC2021: Intra-articular Injections of Mesenchymal Stem Cells Without Adjuvant Therapies for Knee Osteoarthritis (September 2021)

Back to course

Pdf Summary

A systematic review and meta-analysis was conducted to evaluate the effectiveness of intra-articular injections of mesenchymal stem cells (MSCs) without adjuvant therapies for knee osteoarthritis (OA). The review included 19 studies with a total of 440 knees. The results showed that all studies reported an improvement in outcomes after the intervention. The standardized mean differences (SMDs) for the visual analog scale (VAS) for pain at rest and upon exertion were -1.48 and -2.25, respectively. The SMDs for the total Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and total Knee injury and Osteoarthritis Outcome Score were -1.19 and 0.88, respectively. The use of bone marrow MSCs and cultured MSCs were found to be associated with significantly better outcomes compared to adipose MSCs and uncultured MSCs, respectively. Overall, the findings suggest that intra-articular injections of MSCs without adjuvant therapies can improve pain and function for knee OA. The use of bone marrow MSCs and cultured MSCs may further enhance treatment outcomes. However, further research is needed to establish the long-term effects of MSC injections and to compare the efficacy of different sources and culture conditions of MSCs.

Keywords

systematic review

meta-analysis

intra-articular injections

mesenchymal stem cells

knee osteoarthritis

effectiveness

visual analog scale

pain

treatment outcomes

long-term effects